HS3ST5

Across TCGA pan-cancer cohorts, HS3ST5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HS3ST5 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher HS3ST5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HS3ST5 expression acts as an unfavorable survival marker.

SCLC, ESCA, and STAD are the cancer types where HS3ST5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	18	view →
ESCA	OS	Median	All	0.211	0.700	.028	9	view →
STAD	OS	Median	All	0.250	0.729	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HS3ST5–SCLC (DFS)

Open the SCLC breakdown →